Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RVVTF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0160 +40.63%
on 03/07/24
0.0279 -19.35%
on 03/13/24
+0.0005 (+2.27%)
since 02/27/24
3-Month
0.0160 +40.63%
on 03/07/24
0.0360 -37.50%
on 01/23/24
+0.0002 (+0.90%)
since 12/27/23
52-Week
0.0160 +40.63%
on 03/07/24
0.0710 -68.31%
on 04/26/23
-0.0163 (-42.01%)
since 03/27/23

Most Recent Stories

More News
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Top COVID-19 Treatment Stocks Investors Should Consider

The coronavirus isn’t gone just yet. China just imposed new lockdowns in Shanghai, as the city records some of its highest numbers of new COVID-19 cases. Italy just reported another 30,710 cases on...

PFE : 27.78 (+0.69%)
MRNA : 110.59 (+2.96%)
JNJ : 157.96 (+1.41%)
MRK : 131.75 (+4.96%)
RVVTF : 0.0225 (+6.64%)
RVV.CN : 0.0250 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international...

RVV.CN : 0.0250 (unch)
RVVTF : 0.0225 (+6.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0290
2nd Resistance Point 0.0259
1st Resistance Point 0.0242
Last Price 0.0225
1st Support Level 0.0194
2nd Support Level 0.0163
3rd Support Level 0.0146

See More

52-Week High 0.0710
Fibonacci 61.8% 0.0500
Fibonacci 50% 0.0435
Fibonacci 38.2% 0.0370
Last Price 0.0225
52-Week Low 0.0160

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar